(Q36626254)

15 August 2017

1 reference

title

Improving patient outcomes in schizophrenia: achieving remission (English)

1 reference

15 August 2017

0 references

1

Henry A Nasrallah

1 reference

15 August 2017

Rob Lasser

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Journal of Psychopharmacology

15 August 2017

published in

1 reference

15 August 2017

volume

20

1 reference

15 August 2017

issue

6 Suppl

1 reference

15 August 2017

page(s)

57-61

1 reference

Remission in schizophrenia: proposed criteria and rationale for consensus

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Long-term depot antipsychotics. A risk-benefit assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

The complexities of individual financial conflicts of interest

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

The FOCIS international survey on psychiatrists' opinions on cognition in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Does risperidone have a place in the treatment of nonschizophrenic patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Direct transition to long-acting risperidone--analysis of long-term efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Antipsychotic depot medication and attitudes of community psychiatric nurses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Towards consensus in the long-term management of relapse prevention in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

The personal impact of schizophrenia in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Systematic review of patient and nurse attitudes to depot antipsychotic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

Guidelines for depot antipsychotic treatment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071248

21 January 2018

Identifiers

DOI

10.1177/1359786806071248

1 reference

15 August 2017

1 reference